三种微小RNA作为胶质瘤诊断潜在生物标志物的研究

发布时间：2018-05-17 21:26

本文选题：miRNA + 胶质瘤　；参考：《南京医科大学》2017年博士论文

【摘要】：目的:血液中的生物标志物用来帮助诊断胶质瘤越来越受到重视,外周血液中的微小核糖核酸(microRNA;miRNA)与恶性肿瘤的相关性已得到认可。我们通过胶质瘤病人血液标本中miRNA的不同表达的差异,来确定miRNA对胶质瘤的诊断性能。方法:将共47位胶质瘤病人及45位健康志愿者作为研究对象,胶质瘤病人纳入胶质瘤研究组,健康自愿者为健康对照组。Trizol法分离提取研究对象的总RNA,miRNA微阵列获取miRNA差异表达族谱。定量反转录聚合酶链式反应(quantitative Reverse Transcription PCR,qRT-PCR)验证选定的三种 miRNA的表达,建立logistic回归分析,产生的受试者工作特征曲线(receiver operating characteristic curves;ROC)和曲线下面积(the area under the ROC curve;AUC)用来评价这三种微RNA作为胶质瘤生物标志物的诊断性能。结果:微阵列数据显示胶质瘤病人血液中有13种miRNA表达异常,最为显著的是miRNA-17,miRNA-130a,和miRNA-10b的表达显著高于健康对照组(P0.01),进一步研究发现,miRNA-17,miRNA-130a 和 miRNA-10b 的 AUC(95%CI)分别为 0.78(0.69-0.86),0.72(0.62-0.81),0.72(0.62-0.80)。多元logistic回归筛选提示胶质瘤发病与年龄及性别无关,而与miRNA-17,miRNA-130a和miRNA-10b表达成相关性。多元logistic回归预测模型得出的miRNA 回归方程=-5.0+0.55*miR-17+0.40*miR-130a +0.20*miR-10b,此模型方程具有优异的诊断性能:AUC为0.87(0.78-0.93),敏感性为72.3%,特异性为85.1%。结论:上述三种miRNA在胶质瘤病人中显著增高,因此是一种敏感且可靠的新的胶质瘤诊断的生物标志物,且三种特定的miRNA联合检测、分析具有更高的诊断性能。
[Abstract]:Objective: more and more attention has been paid to the use of biomarkers in blood for the diagnosis of gliomas. The relationship between microRNAs in peripheral blood and malignant tumors has been recognized. The differential expression of miRNA in blood samples of glioma patients was used to determine the diagnostic performance of miRNA for glioma. Methods: a total of 47 glioma patients and 45 healthy volunteers were included in the glioma study group. The miRNA differentially expressed genealogy was obtained from the total RNA-miRNA microarray extracted from healthy volunteers by Trizol method. Quantitative reverse transcriptase polymerase chain reaction (Reverse Transcription) quantitative Reverse Transcription qRT-PCR was used to verify the expression of three kinds of miRNA, and logistic regression analysis was established. The receiver operating characteristic curvess-ROC and the area under the curve were used to evaluate the diagnostic performance of these three microRNA as biomarkers of glioma. Results: microarray data showed that there were 13 abnormal miRNA expressions in the blood of glioma patients, the most significant being miRNA-17 miRNA-130 a, and the expression of miRNA-17 miRNA-130 a and miRNA-10b were significantly higher than that of the healthy control group (P0.01a). Further studies showed that the expression of miRNA-17miRNA-130a and miRNA-10b were 0.780.69-0.860.7620.62-0.81a and 0.62-0.80, respectively. Multiple logistic regression analysis showed that glioma had no relationship with age and sex, but was correlated with miRNA-17 miRNA-130a and miRNA-10b expression. The miRNA regression equation obtained from the multivariate logistic regression prediction model was -5.0 0.55*miR-17 0.40*miR-130a 0.20 miR-10b. The model equation had excellent diagnostic performance. The sensitivity was 72.3% and the specificity was 85.1%. Conclusion: these three kinds of miRNA are significantly increased in glioma patients, so they are a sensitive and reliable biomarker for the diagnosis of glioma, and the combined detection of three specific miRNA has higher diagnostic performance.
【学位授予单位】：南京医科大学
【学位级别】：博士
【学位授予年份】：2017
【分类号】：R739.41

【参考文献】